Cholangiocarcinoma Therapeutics
1. Lytgobi patent expiration
Treatment: Method of treating intrahepatic cholangiocarcinoma
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(7 years from now) | |
| US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833151 | TAIHO ONCOLOGY | Pharmaceutical composition including sodium alkyl sulfate |
Nov, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2027 |
| ODE*(ODE*) | Sep 30, 2029 |
| Orphan Drug Exclusivity(ODE-410) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 30 September, 2026
Market Authorisation Date: 30 September, 2022
Dosage: TABLET
More Information on Dosage
LYTGOBI family patents
2. Pemazyre patent expiration
Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement b...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9611267 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jan, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(13 years from now) | |
| US11628162 | INCYTE CORP | Methods of treating cancer with an FGFR inhibitor |
Aug, 2040
(14 years from now) | |
| US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-899) | Aug 26, 2025 |
| Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Dosage: TABLET
More Information on Dosage
PEMAZYRE family patents
3. Tibsovo patent
expiration
Treatment: A method of treating a cancer characterized by an idh1 mutation wherein the cancer is relapsed or refractory myelodysplastic syndromes; A method for treating newly diagnosed aml with ivosidenib and az...
TIBSOVO IPR and PTAB Proceedings
Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(7 years from now) | |
| US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11667673 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(7 years from now) | |
| US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(4 years from now) | |
| US9968595 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(7 years from now) | |
| US10653710 | SERVIER | Combination therapy for treating malignancies |
Oct, 2036
(10 years from now) | |
| US10799490 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(13 years from now) | |
| US10449184 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-816) | May 02, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-893) | May 25, 2025 |
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Dosage: TABLET
How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage
TIBSOVO family patents
4. Truseltiq patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8552002 | HELSINN HLTHCARE | Compounds and compositions as protein kinase inhibitors |
Aug, 2029
(3 years from now) | |
| US9067896 | HELSINN HLTHCARE | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
Aug, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10278969 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(8 years from now) | |
| US11160804 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-353) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Dosage: CAPSULE
More Information on Dosage
TRUSELTIQ family patents